Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years.

In this open, randomized trial the safety, reactogenicity, and immunogenicity profile of a high-dose combined hepatitis A and B candidate vaccine was compared with that of Twinrix Paediatric in healthy volunteers aged 11-18 years.
One hundred subjects were randomly allocated to either of two groups. One group received the high-dose vaccine (720 E1.U HAV antigen; 20 microg hepatitis B surface antigen (HBsAg) at months 0 and 6; the second group received Twinrix Paediatric (360 E1.U HAV antigen; 10 microg HBsAg), following a 0-1-6-month schedule.
Injection site soreness and fatigue were the most frequently reported solicited symptoms. For hepatitis A all subjects had seroconverted at month 7, and geometric mean titres (GMT) were 8,151 mIU/ml in the high-dose group and 6,394 mIU/ml in the Twinrix Paediatric group. For hepatitis B the GMT for the Twinrix Paediatric group was significantly higher at month 2 and month 6. However, no difference in GMT between groups could be established at month 7. The seroprotection rate attained 100% in both groups, and GMT were 4,212 mIU/ml (high-dose group) and 6,330 mIU/ml (Twinrix Paediatric).
The two vaccines showed similar safety and reactogenicity profiles. After completion of the vaccination schedule, no difference in immunogenicity was shown. This high-dose vaccine, administered following a two-dose schedule, can be considered an alternative regimen for the immunization of healthy adolescents against hepatitis A and hepatitis B infections, in a setting where vaccinees are not immediately at risk of exposure to hepatitis B.
AuthorsK Van Herck, P Van Damme, F Collard, S Thoelen
JournalScandinavian journal of gastroenterology (Scand J Gastroenterol) Vol. 34 Issue 12 Pg. 1236-40 (Dec 1999) ISSN: 0036-5521 [Print] NORWAY
PMID10636072 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Hepatitis A Antibodies
  • Hepatitis A Vaccines
  • Hepatitis Antibodies
  • Hepatitis B Antibodies
  • Hepatitis B Vaccines
  • Vaccines, Combined
  • Viral Hepatitis Vaccines
  • Adolescent
  • Child
  • Female
  • Hepatitis A (immunology, prevention & control)
  • Hepatitis A Antibodies
  • Hepatitis A Vaccines
  • Hepatitis Antibodies (blood)
  • Hepatitis B (immunology, prevention & control)
  • Hepatitis B Antibodies (blood)
  • Hepatitis B Vaccines (administration & dosage, adverse effects, immunology)
  • Humans
  • Immunization Schedule
  • Male
  • Risk Factors
  • Vaccines, Combined (administration & dosage, adverse effects, immunology)
  • Viral Hepatitis Vaccines (administration & dosage, adverse effects, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: